All peptides
CognitiveInvestigational

Nemifitide

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Nemifitide is a synthetic pentapeptide analog of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH). It acts on melanocortin receptors, particularly MC4, to modulate inflammatory pathways, oxidative stress, and neuronal excitability.

Mechanism of Action

The peptide has been investigated for neuroprotection in settings of acute brain injury and neurodegenerative disease.

Research Summary & Key Findings

A phase II trial in hemorrhagic stroke patients did not demonstrate significant improvement in functional outcomes or mortality. Additional small studies in traumatic brain injury have been conducted, but robust clinical efficacy data remain limited and no regulatory approvals have been obtained.

Clinical Status

Investigational

Nemifitide is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Cognitive

Start Your Consultation

Get an AI-proposed Nemifitide protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Nemifitide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.